|
Hutchmed China Ltd on Wednesday announced topline results of a phase 3 trial of its selective small molecule inhibitor sovleplenib, in a form of anaemia. The Hong Kong-based developer of treatments for cancer and immunological diseases said the trial in adults with warm antibody autoimmune hemolytic anaemia [wAIHA] in China met its primary endpoint of durable haemoglobin response rate within weeks 5 to 24 of treatment. Fengkui Zhang of the Chinese Academy of Medical Sciences Blood Diseases Hospital, and one of the leading principal investigators of the study, said: ‘Warm antibody autoimmune hemolytic anemia is a highly heterogeneous and often chronically relapsing disease. Patients often experience symptoms like fatigue significantly impacting patients’ quality of life. In severe cases, the disease can become lifethreatening if not managed effectively. The positive topline results from Eslim-02 highlight sovleplenib’s potential to deliver rapid and durable haemoglobin responses in wAIHA patients who have limited options after failing standard therapies. This could represent a meaningful advancement for managing this challenging condition.’ Full results from the Eslim-02 study will be submitted for presentation at an upcoming scientific conference. Hutchmed China plans to submit the new drug application for sovleplenib for wAIHA to the China National Medical Products Administration in the first half of 2026. Hutchmed China shares were 0.5% lower at 210.00 pence each on Wednesday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
